Risk of nonarteritic ischaemic optic neuropathy with phosphodiesterase type 5 inhibitors: a systematic review and meta‐analysis
A Penedones, C Alves… - Acta Ophthalmologica, 2020 - Wiley Online Library
The development of nonarteritic anterior ischaemic optic neuropathy has been described to
phosphodiesterase type 5 inhibitors. The aim of this systematic review and meta‐analysis …
phosphodiesterase type 5 inhibitors. The aim of this systematic review and meta‐analysis …
Risk of nonarteritic ischaemic optic neuropathy with phosphodiesterase type 5 inhibitors: a systematic review and meta-analysis
A Penedones, C Alves… - Acta …, 2020 - pubmed.ncbi.nlm.nih.gov
The development of nonarteritic anterior ischaemic optic neuropathy has been described to
phosphodiesterase type 5 inhibitors. The aim of this systematic review and meta-analysis …
phosphodiesterase type 5 inhibitors. The aim of this systematic review and meta-analysis …
Risk of nonarteritic ischaemic optic neuropathy with phosphodiesterase type 5 inhibitors: a systematic review and meta‐analysis.
A Penedones, C Alves… - Acta Ophthalmologica …, 2020 - search.ebscohost.com
The development of nonarteritic anterior ischaemic optic neuropathy has been described to
phosphodiesterase type 5 inhibitors. The aim of this systematic review and meta‐analysis …
phosphodiesterase type 5 inhibitors. The aim of this systematic review and meta‐analysis …
Risk of nonarteritic ischaemic optic neuropathy with phosphodiesterase type 5 inhibitors: a systematic review and meta-analysis.
A Penedones, C Alves - Acta Ophthalmologica, 2019 - europepmc.org
The development of nonarteritic anterior ischaemic optic neuropathy has been described to
phosphodiesterase type 5 inhibitors. The aim of this systematic review and meta-analysis …
phosphodiesterase type 5 inhibitors. The aim of this systematic review and meta-analysis …